ʻO Ruxolitinib, i kapa ʻia ʻo ruxolitinib ma Kina, ʻo ia kekahi o nā "lāʻau lapaʻau hou" i hoʻopaʻa nui ʻia i nā alakaʻi alakaʻi no ka mālama ʻana i nā maʻi hematological i nā makahiki i hala iho nei, a ua hōʻike ʻo ia i ka maikaʻi o nā maʻi myeloproliferative.
ʻO ka lāʻau lapaʻau ʻo Jakavi ruxolitinib i hoʻopaʻa ʻia e hiki ke kāohi pono i ka hoʻāla ʻana o ke kahawai JAK-STAT holoʻokoʻa a hōʻemi i ka hōʻailona hoʻonui ʻia ʻole o ke kahawai, no laila e loaʻa ai ka pono.Hiki ke hoʻohana ʻia no ka mālama ʻana i nā maʻi like ʻole, a no nā mea ʻino o ka pūnaewele JAK1.
ʻO Ruxolitinibhe kinase inhibitor i hōʻike ʻia no ka mālama ʻana i nā maʻi me ka myelofibrosis waena a i ʻole kiʻekiʻe, me ka myelofibrosis mua, post-geniculocytosis myelofibrosis, a me ka myelofibrosis post-primary thrombocythemia.
A like like clinical study (n=219) randomized maʻi me intermediate-risk-2 aiʻole kiʻekiʻe-pilikia MF mua, nā mea maʻi me MF ma hope o erythroblastosis maoli, a i ole poe maʻi me MF ma hope o thrombocytosis mua i elua hui, hookahi e loaa ana ruxolitinib waha 15 i 20 mgbid (n=146) a ʻo kekahi e loaʻa ana i ka lāʻau hoʻomalu maikaʻi (n=73).ʻO nā kumu mua a me nā koʻikoʻi koʻikoʻi o ke aʻo ʻana, ʻo ia ka pākēneka o nā maʻi me ≥35% ka emi ʻana o ka nui o ka spleen (i loiloi ʻia e ka magnetic resonance imaging a i ʻole computed tomography) i nā pule 48 a me 24, kēlā me kēia.Ua hōʻike nā hualoaʻa i ka pākēneka o nā maʻi i ʻoi aku ma mua o 35% ka hōʻemi ʻana i ka nui o ka spleen mai ka pae kumu ma ka pule 24 he 31.9% i ka hui lapaʻau i hoʻohālikelike ʻia me 0% i ka pūʻulu mana (P<0.0001);a ʻo ka pākēneka o nā maʻi i ʻoi aku ma mua o 35% ka hōʻemi ʻana i ka nui o ka spleen mai ka papa kuhikuhi i ka pule 48 he 28.5% i ka hui lapaʻau i hoʻohālikelike ʻia me 0% i ka pūʻulu mana (P<0.0001).Eia kekahi, ua hōʻemi pū ka ruxolitinib i nā hōʻailona holoʻokoʻa a hoʻomaikaʻi nui i ka maikaʻi o ke ola i nā maʻi.Ma muli o nā hopena o kēia mau hoʻokolohua lapaʻau ʻelua,ruxolitiniblilo i lāʻau lapaʻau mua i ʻae ʻia e ka US FDA no ka mālama ʻana i nā maʻi me MF.